All In Biotech

Drug Trial Radar · NCT07237048

Minocycline in Stroke Study at Maimonides

Effect of Oral Minocycline in Patients With Acute Stroke - a Randomized, Open Label, Prospective Trial

Last checked: Nov 19, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,164 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,164

Planned (sponsor's estimate)

Start

Feb 2, 2026

Primary completion

Dec 1, 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Joyce ChenAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to determine if Minocycline, when added to standard care, can improve survival and functional outcomes in patients with moderate acute stroke (ischemic or hemorrhagic) aged 18 years and older. The main questions it aims to answer are: 1. Does Minocycline improve \*National Institutes of Health Stroke Scale\* (NIHSS) scores at hospital discharge and 90 days post-stroke? 2. Does Minocycline reduce stroke-related disability, all-cause in hospital mortality (mRS -\*Modified Rankin Scale\* = 6) and at 90 days besides reducing brain bleeding complications compared to standard care? Researchers will compare patients receiving oral Minocycline plus standard care to those receiving standard care only to see if Minocycline leads to better neurological outcomes and lower mortality. Participants will: 1. Be randomly assigned by block to receive either: Minocycline 200 mg orally once daily for five days within 24 hours from symptoms onset + Standard Care, or Standard Care only 2. Undergo neurological assessments using NIHSS \*National Institutes of Health Stroke Scale\* and Modified Rankin Scale (mRS) at admission, discharge, 30 days post-stroke, 90 days post-stroke 3. Be monitored for: a) hemorrhagic transformation of ischemic strokes; b) Adverse events and mortality outcomes; c) Safety and efficacy signals through interim analyses NIHSS: \*National Institutes of Health Stroke Scale\*, which is stroke severity scale, mRS: \*Modified Rankin Scale\*, which is stroke disability scale

Conditions

  • Stroke
  • Ischemia Stroke
  • Hemorrhagic Strokes
  • Mortality
  • Morbidity
  • Cerebrovascular Accident (Stroke)
  • Intracerebral Haemorrhage (ICH)

Interventions

  • Minocycline 200mgDrug

    Minocycline 200 mg every 24 hours for five days to be initiated within 24hr of stroke onset.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in National Institutes of Health Stroke Scale (NIHSS) Score at Day 7 post strokeTime frame: At day 7 after stroke onset
  2. Change in National Institutes of Health Stroke Scale (NIHSS) Score at 90 days (+/- 7 days) post-strokeTime frame: At 90 days (+/- 7 days) after stroke onset

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Maimonides Medical Center

    Brooklyn, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.